CSIMarket Company Name, Ticker, Industry, else..
 
Monopar Therapeutics Inc   (NASDAQ: MNPR)
Other Ticker:  
 
 
Price: $29.7500 $0.26 0.882%
Day's High: $30.99 Week Perf: 6.44 %
Day's Low: $ 29.49 30 Day Perf: -41.11 %
Volume (M): 20 52 Wk High: $ 54.30
Volume (M$): $ 607 52 Wk Avg: $11.96
Open: $29.49 52 Wk Low: $0.34



 Market Capitalization (Millions $) 105
 Shares Outstanding (Millions) 4
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Monopar Therapeutics Inc
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of cancer. The company focuses on developing antibody-drug conjugates (ADCs) and immune-modulating therapies with the aim of improving patient outcomes. Monopar's lead product candidate, Validive, is an investigational drug for the treatment of severe oral mucositis caused by chemoradiotherapy. The company is also involved in several collaborations and partnerships to further develop its product pipeline. Overall, Monopar Therapeutics is committed to developing innovative therapies that can address unmet medical needs in the field of oncology.


   Company Address: 1000 Skokie Blvd., Suite 350 Wilmette 60091 IL
   Company Phone Number: 388-0349   Stock Exchange / Ticker: NASDAQ MNPR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.26%    
BMY   -6.5%    
LLY   -1.96%    
MRK   -0.69%    
REGN   -10.47%    
VRTX        0.95% 
• View Complete Report
   



Management Announcement

Monopar Therapeutics: Charting the Course Between Innovation and Financial Struggles

Published Fri, Dec 20 2024 2:01 PM UTC

In a time when the biotechnology sector is brimming with promise and potential, Monopar Therapeutics Inc. (Nasdaq: MNPR) stands out as a beacon of hope?and, paradoxically, concern. The clinical-stage company, dedicated to developing groundbreaking treatments for unmet medical needs, recently secured funding through a public offering and private placement while simultaneously...
Clinical Study

Monopar Therapeutics Breaks Ground with First Patient Dosed in Phase 1 Trials for Revolutionary Cancer Treatment MN...

Published Thu, Dec 5 2024 9:21 PM UTC

In a significant milestone for cancer therapeutics, Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company committed to addressing critical unmet medical needs, has announced the successful dosing of its first patient with a groundbreaking novel therapeutic radiopharmaceutical, MNPR-101-Lu. This development marks a pivotal advance in the company?s m...
Shares

Monopar Therapeutics Seizes Momentum with Public Stock Offering Amid Radiopharmaceutical Innovations

Published Mon, Oct 28 2024 8:00 PM UTC

In a pivotal move underscoring its strategic growth trajectory, Monopar Therapeutics Inc. (Nasdaq: MNPR), a company renowned for spearheading advancements in biotechnology, has announced its intention to offer shares of its common stock in a best efforts public offering. This financial maneuver, revealed on October 28, 2024, represents a calculated stride by the company to c...
Product Service News

Monopar Therapeutics Takes the Lead in Radiopharmaceutical Innovation with New Patent Filing

Published Tue, Oct 15 2024 12:00 PM UTC

In a significant move that could reshape the landscape of cancer treatment, Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced the filing of a provisional patent that expands its portfolio of radiopharmaceutical intellectual property. This strategic initiative, unveiled on October 15, 2024, is focused on new therapeutic radiopharmaceuticals based on a novel family of lin...
Clinical Study

In the ever-evolving landscape of oncology, the dawn of innovative treatments often heralds new hope for pa...

Published Mon, Oct 7 2024 12:01 PM UTC

Innovative Hope: Monopar Therapeutics Launches Pioneering Clinical Trial for uPAR-Targeted Radiopharmaceutical in Advanced Cancers In the ever-evolving landscape of oncology, the dawn of innovative treatments often heralds new hope for patients grappling with advanced cancers. This October, Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical pionee...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com